Abstract：
OBJECTIVE: To clarify clinical features of anti-Ro52 antibody (Ab)-positive polymyositis (PM)/dermatomyositis (DM).
METHODS: We retrospectively examined clinical features and status of anti-Ro52 Ab in patients with PM/DM admitted at the University of Tsukuba Hospital between January 2019 and February 2023. We compared anti-Ro52 Ab-positive and -negative groups.
RESULTS: A total of 40 patients were selected and analyzed. Median age at diagnosis was 61.5 (48.8-69.3) years and 34 cases were female. Twenty-three cases were PM and 17 cases were DM (including 6 clinically amyopathic dermatomyositis: CADM). Twenty-two cases were positive for anti-Ro52 Ab, 14 for anti-ARS Ab, and 6 for anti-MDA5 Ab. Interstitial lung disease (ILD) was detected in 29 cases, 9 of which were rapidly progressive. Glucocorticoid (GC)-resistant cardiomyopathy was detected in 6 cases, malignancy in 3 cases, and Sjögren\'s syndrome (SS) in 4 cases. Of the 22 anti-Ro52 Ab positive cases, only 3 were single-positive and the remaining 19 cases simultaneously had other autoantibodies. Comparing the anti-Ro52 Ab-positive and -negative groups, the frequencies of anti-ARS Ab positivity (63.6% vs. 0%), ILD (95.5% vs. 44.4%), GC-resistant cardiomyopathy (27.3% vs. 0%), concomitant use of immunosuppressants (95.5% vs. 55.6%), and levels of C-reactive protein (CRP) were significantly higher in the anti-Ro52 Ab-positive group (p<0.05). The frequencies of PM/DM, positivity of anti-MDA5 Ab, malignancies, and SS were comparable between groups.
CONCLUSIONS: Anti-Ro52 Ab were frequently positive in PM/DM and anti-Ro52 Ab-positive patients showed significantly higher rates of anti-ARS Ab positivity and ILD, GC-resistant cardiomyopathy, concomitant use of immunosuppressants, and higher levels of CRP. Anti-Ro52 Ab may be useful as a severity marker in PM/DM.
METHODS: We retrospectively examined clinical features and status of anti-Ro52 Ab in patients with PM/DM admitted at the University of Tsukuba Hospital between January 2019 and February 2023. We compared anti-Ro52 Ab-positive and -negative groups.
RESULTS: A total of 40 patients were selected and analyzed. Median age at diagnosis was 61.5 (48.8-69.3) years and 34 cases were female. Twenty-three cases were PM and 17 cases were DM (including 6 clinically amyopathic dermatomyositis: CADM). Twenty-two cases were positive for anti-Ro52 Ab, 14 for anti-ARS Ab, and 6 for anti-MDA5 Ab. Interstitial lung disease (ILD) was detected in 29 cases, 9 of which were rapidly progressive. Glucocorticoid (GC)-resistant cardiomyopathy was detected in 6 cases, malignancy in 3 cases, and Sjögren\'s syndrome (SS) in 4 cases. Of the 22 anti-Ro52 Ab positive cases, only 3 were single-positive and the remaining 19 cases simultaneously had other autoantibodies. Comparing the anti-Ro52 Ab-positive and -negative groups, the frequencies of anti-ARS Ab positivity (63.6% vs. 0%), ILD (95.5% vs. 44.4%), GC-resistant cardiomyopathy (27.3% vs. 0%), concomitant use of immunosuppressants (95.5% vs. 55.6%), and levels of C-reactive protein (CRP) were significantly higher in the anti-Ro52 Ab-positive group (p<0.05). The frequencies of PM/DM, positivity of anti-MDA5 Ab, malignancies, and SS were comparable between groups.
CONCLUSIONS: Anti-Ro52 Ab were frequently positive in PM/DM and anti-Ro52 Ab-positive patients showed significantly higher rates of anti-ARS Ab positivity and ILD, GC-resistant cardiomyopathy, concomitant use of immunosuppressants, and higher levels of CRP. Anti-Ro52 Ab may be useful as a severity marker in PM/DM.
摘要：
目的：阐明抗Ro52抗体（Ab）阳性多发性肌炎（PM）/皮肌炎（DM）的临床特征。
方法：我们回顾性检查了2019年1月至2023年2月在筑波大学医院收治的PM/DM患者的临床特征和抗Ro52Ab状态。我们比较了抗Ro52抗体阳性和阴性组。
结果：共选择40例患者进行分析。诊断时的中位年龄为61.5（48.8-69.3）岁，女性34例。PM23例，DM17例（包括6例临床无肌病性皮肌炎：CADM）。22例抗Ro52抗体阳性,14用于抗ARSAb，和6的抗MDA5Ab。间质性肺病（ILD）29例，其中9个是快速进步的。6例糖皮质激素(GC)抵抗性心肌病,3例恶性肿瘤，干燥综合征(SS)4例。在22例抗Ro52Ab阳性病例中，只有3例单阳性,其余19例同时存在其他自身抗体.比较抗Ro52抗体阳性和阴性组，抗ARSAb阳性的频率(63.6%与0%)，ILD（95.5%vs.44.4%），GC抗性心肌病（27.3%vs.0%)，同时使用免疫抑制剂（95.5%vs.55.6%），抗Ro52Ab阳性组的C反应蛋白（CRP）水平明显升高（p<0.05）。PM/DM的频率，抗MDA5Ab阳性，恶性肿瘤,和SS组间比较。
结论：抗-Ro52Ab在PM/DM中常呈阳性，抗-Ro52Ab阳性患者的抗-ARSAb阳性率和ILD发生率明显较高，抗GC心肌病，同时使用免疫抑制剂，和更高水平的CRP。抗Ro52Ab可用作PM/DM中的严重性标志物。
方法：我们回顾性检查了2019年1月至2023年2月在筑波大学医院收治的PM/DM患者的临床特征和抗Ro52Ab状态。我们比较了抗Ro52抗体阳性和阴性组。
结果：共选择40例患者进行分析。诊断时的中位年龄为61.5（48.8-69.3）岁，女性34例。PM23例，DM17例（包括6例临床无肌病性皮肌炎：CADM）。22例抗Ro52抗体阳性,14用于抗ARSAb，和6的抗MDA5Ab。间质性肺病（ILD）29例，其中9个是快速进步的。6例糖皮质激素(GC)抵抗性心肌病,3例恶性肿瘤，干燥综合征(SS)4例。在22例抗Ro52Ab阳性病例中，只有3例单阳性,其余19例同时存在其他自身抗体.比较抗Ro52抗体阳性和阴性组，抗ARSAb阳性的频率(63.6%与0%)，ILD（95.5%vs.44.4%），GC抗性心肌病（27.3%vs.0%)，同时使用免疫抑制剂（95.5%vs.55.6%），抗Ro52Ab阳性组的C反应蛋白（CRP）水平明显升高（p<0.05）。PM/DM的频率，抗MDA5Ab阳性，恶性肿瘤,和SS组间比较。
结论：抗-Ro52Ab在PM/DM中常呈阳性，抗-Ro52Ab阳性患者的抗-ARSAb阳性率和ILD发生率明显较高，抗GC心肌病，同时使用免疫抑制剂，和更高水平的CRP。抗Ro52Ab可用作PM/DM中的严重性标志物。
